CDK2-IN-41

Overview

CDK2-IN-41 (Compound 7a) is a CDK2 inhibitor that exerts anticancer activity by binding to CDK2 , thereby inhibiting the cell cycle, inducing cytotoxicity, promoting ROS production, and triggering Apoptosis . CDK2-IN-41 exhibits an IC 50 of 10 µM against acute myeloid leukemia (AML) HL-60 cells. It holds potential for research in AML-related cancer therapy.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-172153
• CAS No.: 3078696-37-1
• Molecular Formula: C19H21N3S
• Molecular Weight: 323.46
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source